From Despair to Promise: The Dawn of Novel Treatment in IgA Nephropathy.
作者信息
Tang Sydney C W, Nadkarni Girish N
机构信息
Division of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
J Am Soc Nephrol. 2025 Apr 1;36(4):541-543. doi: 10.1681/ASN.0000000551. Epub 2024 Oct 26.
Abstract
摘要
相似文献
1
From Despair to Promise: The Dawn of Novel Treatment in IgA Nephropathy.从绝望到希望：IgA肾病新型治疗方法的曙光
J Am Soc Nephrol. 2025 Apr 1;36(4):541-543. doi: 10.1681/ASN.0000000551. Epub 2024 Oct 26.
2
Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report.用iptacopan成功靶向替代补体途径治疗IgA肾病：一例病例报告。
Swiss Med Wkly. 2025 Jun 30;155:4435. doi: 10.57187/s.4435.
3
Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review.儿童IgA肾病与成人IgA肾病不同吗？一篇叙述性综述。
Can J Kidney Health Dis. 2025 Mar 12;12:20543581251322571. doi: 10.1177/20543581251322571. eCollection 2025.
4
The Proportion of New-Onset Microangiopathic Lesions in IgA Nephropathy is Increased After COVID-19 Pandemic in China.中国新冠疫情后IgA肾病中新发微血管病变的比例增加。
Kidney Med. 2025 Jun 3;7(8):101043. doi: 10.1016/j.xkme.2025.101043. eCollection 2025 Aug.
5
Transcriptomic Patterns in Adult and Pediatric Patients with IgA Nephropathy or IgA Vasculitis with Nephropathy.成人及儿童IgA肾病或IgA血管炎伴肾病的转录组学模式
J Am Soc Nephrol. 2025 Jul 1. doi: 10.1681/ASN.0000000787.
6
Efficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: a case series.泰吉华单抗治疗青少年IgA肾病和IgA血管炎肾病的疗效及安全性：病例系列
Pediatr Nephrol. 2025 Jul 25. doi: 10.1007/s00467-025-06905-z.
7
Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂治疗儿童 IgA 肾病的疗效和安全性。
Pediatr Nephrol. 2022 Mar;37(3):499-508. doi: 10.1007/s00467-021-05316-0. Epub 2021 Oct 22.
8
Differential Cell-Specific, Regulatory Roles of FcγRIIB through IgG in IgA Nephropathy.FcγRIIB通过IgG在IgA肾病中的细胞特异性差异调节作用
J Am Soc Nephrol. 2025 Aug 21. doi: 10.1681/ASN.0000000835.
9
County-Level Income Inequality, Social Mobility, and Deaths of Despair in the US, 2000-2019.2000-2019 年美国县级收入不平等、社会流动性与绝望死亡
JAMA Netw Open. 2023 Jul 3;6(7):e2323030. doi: 10.1001/jamanetworkopen.2023.23030.
10
Potential benefits and related treatment effects of calcineurin inhibitors combined with steroid for IgA nephropathy: a systematic review and meta-analysis.钙调磷酸酶抑制剂联合激素治疗 IgA 肾病的潜在获益及相关作用：系统评价和荟萃分析。
Int Urol Nephrol. 2023 Sep;55(9):2227-2236. doi: 10.1007/s11255-023-03524-1. Epub 2023 Mar 1.
本文引用的文献
1
The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial.选择性内皮素受体拮抗剂SC0062治疗IgA肾病：一项随机双盲安慰剂对照临床试验
J Am Soc Nephrol. 2025 Apr 1;36(4):657-667. doi: 10.1681/ASN.0000000538. Epub 2024 Oct 26.
2
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy.阿他西普治疗IgA肾病开放标签扩展研究的长期结果
J Am Soc Nephrol. 2025 Apr 1;36(4):679-687. doi: 10.1681/ASN.0000000541. Epub 2024 Oct 26.
3
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.ravulizumab治疗IgA肾病的疗效与安全性：一项2期随机双盲安慰剂对照试验
J Am Soc Nephrol. 2025 Apr 1;36(4):645-656. doi: 10.1681/ASN.0000000534. Epub 2024 Oct 25.
4
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.一项评估阿他西普治疗IgA肾病的2b期随机双盲安慰剂对照临床试验。
Kidney Int. 2024 Jun;105(6):1306-1315. doi: 10.1016/j.kint.2024.03.012. Epub 2024 Mar 27.
5
Targeting complement in IgA nephropathy.靶向治疗IgA肾病中的补体。
Clin Kidney J. 2023 Dec 4;16(Suppl 2):ii28-ii39. doi: 10.1093/ckj/sfad198. eCollection 2023 Dec.
6
IgA nephropathy.IgA 肾病。
Nat Rev Dis Primers. 2023 Nov 30;9(1):67. doi: 10.1038/s41572-023-00476-9.
7
Targeting the Endothelin A Receptor in IgA Nephropathy.靶向内皮素A受体治疗IgA肾病
Kidney Int Rep. 2023 Aug 4;8(11):2198-2210. doi: 10.1016/j.ekir.2023.07.023. eCollection 2023 Nov.
8
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.在 IgA 肾病患者中，sparsentan 对比厄贝沙坦的疗效和安全性（PROTECT）：一项随机、活性对照、3 期临床试验的 2 年结果。
Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3.
9
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.一项随机双盲安慰剂对照的2期研究结果表明，iptacopan可作为IgA肾病的替代补体途径抑制剂。
Kidney Int. 2024 Jan;105(1):189-199. doi: 10.1016/j.kint.2023.09.027. Epub 2023 Oct 31.
10
Recent advances in the physiopathology of IgA nephropathy.IgA肾病生理病理学的最新进展
Nephrol Ther. 2018 Apr;14 Suppl 1:S1-S8. doi: 10.1016/j.nephro.2018.02.004.
Zotero 插件